UK-based pharmaceutical company N4 Pharma has issued 1.5 million ordinary shares priced at £0.085 ($0.12) a share in a private placement to raise gross proceeds of £0.012m ($0.016m).

Venture capital firm Segulah Venture has agreed to invest Skr15m ($1.9m) in medical technology company Senzime.

Related Company Profiles

View all

The investment is part of Senzime’s issue of 4.1 million shares priced at Skr6 ($0.75) a share in a private placement to raise Skr25m ($3.15m).

Segulah Venture’s investment will enable Senzime to acquire capital and strengthen its ownership base.

Advokatfirman Lindahl has been appointed as the legal advisor for the transaction.

Irish specialist pharmaceutical company Allergan has filed a registration statement with the US Securities and Exchange Commission (SEC) for a public offering of securities.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“Venture capital firm Segulah Venture has agreed to invest Skr15m ($1.9m) in medical technology company Senzime.”

Allergan will offer and sell ordinary shares, serial preferred shares, as well as purchase contracts for ordinary shares and depositary shares, and purchase units comprised of ordinary shares following the registration.

The company’s subsidiary Allergan Funding SCS (Allergan SCS) can also offer and sell senior debt securities.

The company plans to use the proceeds for general corporate purposes, including acquisitions or debt repayment.

AstraZeneca has licensed Ionis Pharmaceuticals’ antisense drug IONIS-AZ5-2.5Rx (AZD2373), which is indicated for the treatment of kidney disease.

AstraZeneca will pay $30m as an upfront payment and another $300m upon achieving development and regulatory milestones.

Based in the UK, AstraZeneca is a pharmaceutical company, while Ionis Pharmaceuticals is a biopharmaceutical company also based in the UK.